[Ip-health] Novartis, Dana Farber, Oregon Health & Science University Wait 18 Years to Disclose NIH Funding in Key Gleevec Patent | Bill of Health

Alicia Mundy amundy at aliciamundy.com
Fri Oct 11 09:29:56 PDT 2019


This is HUGE news! That you can show it at last. 

Alicia Mundy
Washington 
202-360-3950


> On Oct 11, 2019, at 11:57 AM, James Love <james.love at keionline.org> wrote:
> 
> After 18 years, Novartis gets around to disclosing NIH funding in a Gleevec
> patent.
> 
> Jamie
> 
> 
> http://blog.petrieflom.law.harvard.edu/2019/10/11/novartis-dana-farber-oregon-health-science-university-wait-18-years-to-disclose-nih-funding-in-key-gleevec-patent/
> 
> This is a story about U.S. patent number 6,958,335, and how it took more
> than 18 years for Novartis to acknowledge National Institutes of Health
> (NIH) funding in a key patent for Gleevec, allowing Novartis to shape the
> narrative regarding its role in the development of Gleevec, and also to
> avoid demands that Novartis make the invention “available to the public on
> reasonable terms,” which is an obligation under the Bayh-Dole Act.
> ....
> _______________________________________________
> Ip-health mailing list
> Ip-health at lists.keionline.org
> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org


More information about the Ip-health mailing list